Intramyocardial injection of autologous bone marrow cells in no-option patients with refractory angina pectoris and documented ischemia; a registry.

eiden University Medical Center (LUMC), Department of Cardiology0 sites150 target enrollmentTBD

Conditionsbone marrow cells, stem cell therapy, refractory angina, intramyocardial injection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: bone marrow cells, stem cell therapy, refractory angina, intramyocardial injection
Sponsor: eiden University Medical Center (LUMC), Department of Cardiology
Enrollment: 150
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

eiden University Medical Center (LUMC), Department of Cardiology

Eligibility Criteria

Inclusion Criteria

•1\. Severe refractory angina despite optimal medical therapy;
•2\. Reversible ischemia on GATED\-SPECT;

Exclusion Criteria

•1\. Acute myocardial infarction, PCI or CABG within 6 months of enrolment in the study;
•2\. History of malignancy (except low grade and fully resolved non\-melanoma skin malignancy);

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 3

Intramyocardial TransPlantation Of BonE MaRrow Stem Cells For ImprovEment Of Post-Infarct MyoCardial RegeneraTion In Addition To CABG Surgery: a controlled prospective, randomized, double blinded multicenter trial. (PERFECT)Patients with coronary artery disease scheduled for CABG surgery

DRKS00000213Miltenyi Biotec GmbH82

Unknown

Not Applicable

The efficacy of intramyocardial injection of bone marrow-derived mesenchymal and CD133+ stem cells on improvement of cardiac ejection fraction in patients undergoing CABG in Shariati HospitalChronic ischemic heart Disease.Myocardial Infarction

IRCT138902113799N2Technology cooperation office of Persidency9

Active, not recruiting

Not Applicable

After myocardial infarction patients suffer from insufficient blood and oxygen supply. This often results in a reduced heart function attributed to irreversible loss of viable cardiomyocytes. The aim of the study is to determine whether injection of the patient’s own bone marrow stem cells yields an additional benefit to coronary artery bypass graft (CABG) surgery.

EUCTR2006-006404-11-DEMiltenyi Biotec GmbH142

Suspended

Phase 2

Intramyocardial Delivery of Autologous Bone MarrowRefractory Angina

NCT00820586IRCCS San Raffaele13

Completed

Phase 1

Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)Chronic Myocardial Ischemia

NCT02059681Centro Cardiologico Monzino12